Phoenix Rising Companies Announces Morpheus Robotics Acquisition Progress and Dental Implant Product Developments
Phoenix Rising Companies Announces Morpheus Robotics Acquisition Progress and Dental Implant Product Developments
PARK CITY, UT / ACCESSWIRE / October 13, 2022 / Phoenix Rising Companies OTCMarkets PINK:PRCX:
德克薩斯州帕克城/ACCESSWIRE/2022年10月13日/鳳凰城新興公司場外交易市場粉色:PRCX:
DS Chang, CEO and Chairman of the company is pleased to announce progress towards the previously announced planned acquisition of Morpheus Robotics, Inc. Morpheus was originated and has continuing operations in Italy.
該公司首席執行官兼董事長DS Chang高興地宣佈,先前宣佈的收購Morpheus Robotics,Inc.的計劃取得了進展。Morpheus最初是Morpheus Robotics公司,目前繼續在意大利開展業務。
While in the current pre-financing stage DS Chang continues to work with Massimo Strada and Stephen Lee of Morpheus. The Morpheus team has kept DS and Phoenix informed of ongoing advances in Morpheus product development.
在目前的前期融資階段,DS Chang繼續與Morpheus的Massimo Strada和Stephen Lee合作。Morpheus團隊一直向DS和Phoenix通報Morpheus產品開發的持續進展。
The product of greatest interest currently is Morpheus' robotic devices for dental implantation. These machines, when finished and deployed, will aid oral surgeons to implant replacement teeth in patients with highly improve accuracy, greatly reducing both complications and pain. Further, use of the Morpheus machinery saves time and money.
目前最受關注的產品是Morpheus用於牙科種植的機器人設備。這些機器完成並部署後,將幫助口腔外科醫生極大地提高準確性,為患者植入替換牙齒,極大地減少併發症和痛苦。此外,使用Morpheus機器可以節省時間和金錢。
The Parties are working to complete the Share Exchange Agreement as soon as possible to be followed by the closing between the entities.
雙方正在努力盡快完成《換股協議》,以便在兩個實體之間完成交易。
Further developments will be announced.
進一步的進展將另行公佈。
ABOUT MORPHEUS: Morpheus Medical Robotic System is the result of an unprecedented combination of Artificial Intelligence Based Software, new generation medical imaging, holographic reality, robotic applications, pervasive sensors natively integrated, delivering a new and unique minimally invasive robotic surgery ecosystem.
關於Morpheus:Morpheus醫療機器人系統是基於人工智能的軟件、新一代醫學成像、全息現實、機器人應用、本地集成的無處不在的傳感器前所未有地結合在一起的結果,提供了一個新的、獨特的微創機器人手術生態系統。
The Morpheus Super-Calculus GPU Based Appliance is a parallel vectorial supercomputing machine able to process 40 trillion operations per second guaranteeing a fluid ultra-high definition 4X4K, ultra-fast artificial intelligence segmentation, real-time Holographic mixed reality modeling, real-time visual guidance self-alignment.
基於Morpheus Super-Calculus GPU的Appliance是一款並行向量超級計算器,能夠每秒處理40萬億次運算,確保流暢的超高清4X4K、超高速人工智能分割、實時全息混合現實建模、實時視覺制導自對準。
Morpheus started with and continues to use a primary engineering team in Milan, Italy.
Morpheus最初在意大利米蘭使用一支主要的工程團隊,現在仍在使用。
PHOENIX COMMENTS DS Chang, CEO of Phoenix reminds readers of his prior comments, to wit, "This acquisition, if completed, represents a move towards Westernizing Phoenix with new acquisitions that offer a substantial possibility of incredible growth of the company and its stake holders"
鳳凰衞視首席執行官DS Chang提醒讀者他之前的評論,也就是説,如果完成這次收購,代表着鳳凰城西化的一步,新的收購將為公司及其股東提供令人難以置信的增長的巨大可能性。
For information on Phoenix Rising Companies, visit .
contact ir@phoenix-cos.com
有關鳳凰崛起公司的信息,請訪問。
聯繫ir@Phoenix-Cos.com
CAUTIONARY STATEMENT
警示聲明
This press release contains forward-looking statements. Known and unknown risks may cause actual future results to vary widely. The statements are based upon Management's and Advisor's current expectations, estimates and projections; are not guarantees of future performance and are subject to certain risks and uncertainties and other factors, some of which are beyond Management's control and are difficult to predict. A reader of this press release should not place undue reliance on forward-looking statements. Investors should understand investing in shares of PRCX involves a high degree of risk and should seek competent investment advice prior to purchasing shares.
本新聞稿包含前瞻性陳述。已知和未知的風險可能會導致未來的實際結果大相徑庭。這些陳述是基於管理層和顧問公司目前的預期、估計和預測;不是對未來業績的保證,受到某些風險、不確定因素和其他因素的影響,其中一些因素是管理層無法控制的,很難預測。本新聞稿的讀者不應過分依賴前瞻性陳述。投資者應該明白投資PRCX的股票涉及高度風險,在購買股票之前應該尋求稱職的投資建議。
SOURCE: Phoenix Rising Companies
資料來源:鳳凰新秀公司